Sarc | MedPath

Nirogacestat Shows Deepening Long-Term Responses in Desmoid Tumor Patients

2 months ago

• Long-term treatment with nirogacestat (Ogsiveo) demonstrated improved objective response rates reaching 45.7% at 4 years compared to 34.3% at 1 year in patients with desmoid tumors, according to updated DeFi trial data. • Patients experienced significant quality-of-life benefits with nirogacestat, including rapid pain reduction within two weeks of treatment initiation, allowing many to discontinue opioid medications despite minimal initial changes in tumor imaging. • While 75% of female patients experienced reversible ovarian dysfunction with nirogacestat, the study confirmed that ovarian function returned in all patients who discontinued treatment, providing important reassurance for the predominantly young female patient population.

Pembrolizumab Improves Disease-Free Survival in Soft Tissue Sarcoma Patients

6 months ago

• A clinical trial showed that adding pembrolizumab to standard treatment significantly improved disease-free survival in patients with advanced soft tissue sarcoma. • The two-year disease-free survival rate increased from 52% in the control group to 67% in the group receiving pembrolizumab plus standard care. • While adverse events were more frequent in the pembrolizumab group, there were no treatment-related deaths, suggesting it may be a less toxic option than chemotherapy. • Researchers hope the findings will lead to broader use of immunotherapy in treating soft tissue sarcoma and ultimately improve overall survival.